2026-04-17T00:43:02Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/50662025-10-24T10:35:23Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Torres-Salido, Maria Teresa
author
Sanchis Marin, Mireia
author
Solé Marce, Cristina
author
Moline Marimon, Teresa
author
Vidal, Marta
author
Vidal Guitart, Xavier
author
Ordi Ros, José
author
Cortés Hernandez, Josefina
2025-10-24T10:35:23Z
2025-10-24T10:35:23Z
2020-07-06T13:03:45Z2020-07-06T13:03:45Z2019-09-17
http://hdl.handle.net/11351/5066
Neuropilin-1; Lupus nephritis; Urinary biomarkerNeuropilina-1; Nefritis lúpica; Biomarcador urinarioNeuropilina-1; Nefritis per lupus; Biomarcador urinariAt present, Lupus Nephritis (LN) is still awaiting a biomarker to better monitor disease activity, guide clinical treatment, and predict a patient’s long-term outcome. In the last decade, novel biomarkers have been identified to monitor the disease, but none have been incorporated into clinical practice. The transmembrane receptor neuropilin-1 (NRP-1) is highly expressed by mesangial cells and its genetic deletion results in proteinuric disease and glomerulosclerosis. NRP-1 is increased in kidney biopsies of LN. In this work we were interested in determining whether urinary NRP-1 levels could be a biomarker of clinical response in LN. Our results show that patients with active LN have increased levels of urinary NRP-1. When patients were divided according to clinical response, responders displayed higher urinary and tissue NRP-1 levels at the time of renal biopsy. Areas under the receiver operating characteristic curve, comparing baseline creatinine, proteinuria, urinary NRP-1, and VEGFA protein levels, showed NRP-1 to be an independent predictor for clinical response. In addition, in vitro studies suggest that NRP-1could promote renal recovery through endothelial proliferation and migration, mesangial migration and local T cell cytotoxicity. Based on these results, NRP-1 may be used as an early prognostic biomarker in LN.This work was supported by grants from the Spain Government (Instituto de Salud Carlos III). This research also received donations from Catalan Lupus Foundation and A.Bosch Foundation.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Lupus eritematós sistèmic
Marcadors bioquímics
Prognosi
DISEASES::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Neuropilins::Neuropilin-1
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes::lupus eritematoso sistémico::nefritis lúpica
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::neuropilinas::neuropilina-1
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico
Urinary neuropilin-1: a predictive biomarker for renal outcome in lupus nephritis
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion